Amagma Therapeutics specializes in the discovery and development of antibody therapeutics against inflammatory diseases.
Amagma Therapeutics has raised $2.3M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2022.
Amagma Therapeutics's investors include Polaris Partners, Magnetic Ventures.
Amagma Therapeutics is headquartered in Waltham, United States.
Amagma Therapeutics specializes in the discovery and development of antibody therapeutics against inflammatory diseases.
Amagma Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amagma Therapeutics — Funding & Investors." VCBacked, June 1, 2022, https://www.vcbacked.co/company/amagma-therapeutics. Accessed November 15, 2026.
VCBacked. (2022). Amagma Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/amagma-therapeutics
{{cite web |title=Amagma Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/amagma-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Amagma Therapeutics? Request a listing update